Simple blood test could guide breast cancer treatment

NCT ID NCT07670182

Not yet recruiting Knowledge-focused Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test can predict how well the drug deruxtepruzumab works in people with advanced breast cancer that has low or ultra-low levels of a protein called HER2. Researchers will track cancer cells and HER2 levels in the blood of 100 patients during treatment. The goal is to see if these blood markers can help doctors personalize therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Deruxtepruzumab (also called T-DXd, an anti-HER2 antibody-drug conjugate)
What this could lead to: If successful, this could help doctors use a simple blood test to decide which patients are most likely to benefit from deruxtepruzumab, making treatment more personalized.
What could go wrong: This is an early-stage observational study with only 100 participants, so results may not apply to everyone. The blood test may not reliably predict treatment response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PATIENTS WITH LOW HER2 EXPRESSION (IHC 1+ OR IHC 2+/ISH-) AND HER2 IHC 0 ADVANCED BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.